Glaukos Corp Ownership

GKOS Stock  USD 138.44  0.18  0.13%   
Glaukos Corp has a total of 55.14 Million outstanding shares. The majority of Glaukos Corp outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Glaukos Corp to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Glaukos Corp. Please pay attention to any change in the institutional holdings of Glaukos Corp as this could imply that something significant has changed or is about to change at the company. Also note that almost one million six hundred fourty-eight thousand six hundred eight invesors are currently shorting Glaukos Corp expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
2013-03-31
Previous Quarter
50.7 M
Current Value
55 M
Avarage Shares Outstanding
36.2 M
Quarterly Volatility
14.1 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Glaukos Corp in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Glaukos Corp, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividends Paid is likely to drop to about 7.1 M in 2024. Dividend Paid And Capex Coverage Ratio is likely to drop to -3 in 2024. Common Stock Shares Outstanding is likely to drop to about 37 M in 2024. Net Loss is likely to gain to about (84.8 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Glaukos Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Glaukos Stock please use our How to Invest in Glaukos Corp guide.

Glaukos Stock Ownership Analysis

About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.64. Glaukos Corp recorded a loss per share of 2.92. The entity had not issued any dividends in recent years. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. Glaukos Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 727 people. To learn more about Glaukos Corp call Thomas Burns at 949 367 9600 or check out https://www.glaukos.com.
Besides selling stocks to institutional investors, Glaukos Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Glaukos Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Glaukos Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Glaukos Corp Quarterly Liabilities And Stockholders Equity

926.54 Million

Glaukos Corp Insider Trades History

Roughly 3.0% of Glaukos Corp are currently held by insiders. Unlike Glaukos Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Glaukos Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Glaukos Corp's insider trades
 
Yuan Drop
 
Covid

Glaukos Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Glaukos Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Glaukos Corp backward and forwards among themselves. Glaukos Corp's institutional investor refers to the entity that pools money to purchase Glaukos Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Primecap Management Company2024-09-30
1.2 M
Morgan Stanley - Brokerage Accounts2024-06-30
1.2 M
Geode Capital Management, Llc2024-06-30
1.1 M
Artisan Partners Limited Partnership2024-06-30
M
Driehaus Capital Management Llc2024-06-30
803.6 K
Gilder Gagnon Howe & Co Llc2024-06-30
633.9 K
Point72 Asset Management, L.p.2024-06-30
570 K
Loomis, Sayles & Company Lp2024-06-30
554.2 K
Wellington Management Company Llp2024-06-30
553.5 K
Blackrock Inc2024-06-30
M
Fmr Inc2024-06-30
6.8 M
Note, although Glaukos Corp's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Glaukos Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Glaukos Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Glaukos Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Glaukos Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Glaukos Corp Outstanding Bonds

Glaukos Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Glaukos Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Glaukos bonds can be classified according to their maturity, which is the date when Glaukos Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Glaukos Corp Corporate Filings

13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
5th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
4th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
1st of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Glaukos Stock Analysis

When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.